Precision Stock Today

DTIL -  USA Stock  

USD 12.58  0.14  1.13%

Precision Biosciences is selling for 12.58 as of the 16th of September 2021. This is a 1.13 percent up since the beginning of the trading day. The stock's lowest day price was 12.11. Precision Biosciences has a very small chance of experiencing financial distress in the next few years and had a strong performance during the last 90 days. Equity ratings for Precision Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of August 2021 and ending today, the 16th of September 2021. Click here to learn more.
 Market Performance
27 of 100
  Odds Of Distress
Less than 1

Precision Biosciences Stock Profile

The next fiscal quarter end is expected on the 30th of September 2021. Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Precision Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 236 people. more on Precision Biosciences
Precision Biosciences appears to be risky and price may revert if volatility continues
Precision Biosciences is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 101.36 M. Net Loss for the year was (46.5 M) with profit before overhead, payroll, taxes, and interest of 24.29 M.
Precision Biosciences has a poor financial position based on the latest SEC disclosures
About 56.0% of the company shares are held by institutions such as insurance companies
Latest headline from Precision gains 2.81 percent for September 15 -
Precision Biosciences Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Precision Biosciences SEC Filings
Precision Biosciences SEC Filings Security & Exchange Commission EDGAR Reports
Legal NamePrecision Biosciences
CEO, Co-FounderMatthew Kane  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Precision Biosciences report their recommendations after researching Precision Biosciences' financial statements, talking to executives and customers, or listening in on Precision Biosciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Precision Biosciences. The Precision consensus assessment is calculated by taking the average forecast from all of the analysts covering Precision Biosciences.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Precision Biosciences based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Precision Biosciences financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares45.6 M52 M
Fairly Down
Slightly volatile
Weighted Average Shares Diluted45.6 M52 M
Fairly Down
Slightly volatile
Total Assets165.4 M150.2 M
Significantly Up
Slightly volatile
Total Liabilities113.6 M105.7 M
Notably Up
Slightly volatile
Current Assets124.9 M105.6 M
Fairly Up
Slightly volatile
Current Liabilities36 M42.8 M
Fairly Down
Slightly volatile
Total Debt9.4 M9.5 M
Slightly Down
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Asset Turnover0.130.135
Sufficiently Down
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Precision Biosciences' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyUndervalued
Financial Strength
Precision Biosciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Precision Biosciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Precision Biosciences' financial leverage. It provides some insight into what part of Precision Biosciences' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Precision Biosciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Precision Biosciences deploys its capital and how much of that capital is borrowed.
Precision Biosciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 12.01 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. Precision Biosciences has a current ratio of 5.09, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(94.28 Million)Share
Precision Biosciences (DTIL) is traded on NASDAQ Exchange in USA. It is located in 302 East Pettigrew Street and employs 236 people. Precision Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 731.72 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Precision Biosciences's market, we take the total number of its shares issued and multiply it by Precision Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Precision Biosciences conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 57.48 M outstanding shares of which 2.95 M shares are currently shorted by private and institutional investors with about 8.45 trading days to cover. Precision Biosciences currently holds about 173.94 M in cash with 1.06 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.92.
Check Precision Biosciences Probability Of Bankruptcy
Precision Biosciences owns a total of fifty-seven million four hundred eighty thousand outstanding shares. Over half of Precision Biosciences outstanding shares are owned by third-party entities. These third-party entities are typically referred to corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Precision Biosciences. Please watch out for any change in the institutional holdings of Precision Biosciences as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Precision Ownership Details

Precision Stock Price Odds Analysis

What are Precision Biosciences' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Precision Biosciences jumping above the current price in 90 days from now is about 28.88%. The Precision Biosciences probability density function shows the probability of Precision Biosciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.9636 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Precision Biosciences will likely underperform. Moreover, the company has an alpha of 1.6518, implying that it can generate a 1.65 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 12.58HorizonTargetOdds Up 12.58 
71.02%90 days
Based on a normal probability distribution, the odds of Precision Biosciences to move above the current price in 90 days from now is about 28.88 (This Precision Biosciences probability density function shows the probability of Precision Stock to fall within a particular range of prices over 90 days) .

Precision Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Precision Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Precision Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Precision Biosciences' value.
InstituionSecurity TypeTotal SharesValue
Capital World InvestorsCommon Shares4.3 M53.4 M
Blackrock IncCommon Shares3.9 M48.9 M
View Precision Biosciences Diagnostics

Precision Biosciences Historical Income Statement

Precision Biosciences Income Statement is one of the three primary financial statements used for reporting Precision's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Precision Biosciences revenue and expense. Precision Biosciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
The value of Consolidated Income is estimated to pull down to about (111.9 M). The value of Earning Before Interest and Taxes EBIT is expected to pull down to about (111.9 M) View More Fundamentals

Precision Stock Against Markets

Picking the right benchmark for Precision Biosciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Precision Biosciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Precision Biosciences is critical whether you are bullish or bearish towards Precision Biosciences at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Precision Biosciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now


Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Precision Biosciences Corporate Executives

Elected by the shareholders, the Precision Biosciences' board of directors comprises two types of representatives: Precision Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Precision. The board's role is to monitor Precision Biosciences' management team and ensure that shareholders' interests are well served. Precision Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Precision Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Continue to Investing Opportunities. Note that the Precision Biosciences information on this page should be used as a complementary analysis to other Precision Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Precision Stock analysis

When running Precision Biosciences price analysis, check to measure Precision Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Precision Biosciences is operating at the current time. Most of Precision Biosciences' value examination focuses on studying past and present price action to predict the probability of Precision Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Precision Biosciences' price. Additionally, you may evaluate how the addition of Precision Biosciences to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Global Correlations
Find global opportunities by holding instruments from different markets
The market value of Precision Biosciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Precision Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision Biosciences' market value can be influenced by many factors that don't directly affect Precision Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Precision Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.